MEA Varicose Vein Treatment Market

MEA Varicose Vein Treatment Market Size

The Middle East & Africa (MEA) Varicose Vein Treatment Market is projected to grow from USD 23.05 million in 2025 to USD 24.26 million in 2026 and reach USD 36.53 million by 2034, registering a CAGR of 5.25% from 2026 to 2034.

The rising incidence of varicose veins primarily drives the varicose vein treatment market. This condition of enlarged, gnarled veins, appearing mostly in the feet and legs, is caused by several factors, including pregnancy, hormonal changes, genetic disorders, obesity, sleep disorders, high blood pressure levels, and lifestyle-associated factors such as prolonged standing and increased stress levels.

The market is majorly driven by bettering patient compliance owing to the advent of durable and safe techniques to address the huge burden of varicose vein incidences and the increased access to varicose vein medical devices. The healthcare industry has also experienced a new trend of removing or destroying the surface veins with enhanced patient experience. However, the dearth of trained vascular surgeons and the high cost of varicose vein treatment procedures can hinder this market's growth.

MARKET SEGMENTATION

This research report segmented and sub-segmented the Middle East and Africa Varicose Vein Treatment Market into the following categories.

By Treatment Types:

• Surgical Treatments
  • Vein Ligation and Stripping
  • Phlebectomy
• Non-Surgical Treatments
  • Laser Therapy
  • Trans-Illuminated Powered Phlebectomy (Trivex)
• Radiofrequency Ablation
  • Sclerotherapy

By Device:

• Ablation devices
  • Radiofrequency Ablation Devices
  • Laser Ablation Devices
• Venous Closure Products
• Surgical Products

By End-User:

• Surgery Centres
• Hospitals
  • Specialty Hospitals
  • Multispecialty Hospitals

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Some of the companies leading the Middle East & Africa Varicose Vein Treatment Market profiled in the report are Medtronic plc (Ireland), AngioDynamics, Inc. (U.S.), biolitec AG (Austria), Syneron Medical Ltd. (Israel), Lumenis Ltd. (Israel), Dornier MedTech GmbH (Germany), Energist Group (U.K.), Eufoton s.r.l. (Italy), Vascular Solutions, Inc. (U.S.), Quanta System S.p.A. (Italy), Sciton, Inc. (U.S.), Fotona d.o.o. (Slovenia), BTG plc (U.K.), Merz Aesthetics (U.S.).